Diabetes, Microbiome, and Inflammation: Mechanisms and Therapeutic Perspectives

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (30 April 2026) | Viewed by 481

Special Issue Editors


E-Mail Website
Guest Editor
Research Institute of the University of Bucharest-ICUB, University of Bucharest, Bucharest, Romania
Interests: microbiome; metagenomics; gut microbiota; microbial diversity; antimicrobials
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Pathophysiology and Immunology Department, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2. National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania.
Interests: microbiome; diabetes; gut microbiota
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diabetes mellitus remains a pressing global health challenge, with increasing incidence and complex systemic complications. Despite decades of research, the underlying pathogenic mechanisms have not yet been fully elucidated. Recent advances highlight the central role of the microbiome in shaping host metabolism, immunity, and inflammatory pathways. Dysbiosis and chronic low-grade inflammation are now recognized as key drivers of both the onset and progression of diabetes and related complications.

This Special Issue will provide a platform for multidisciplinary discussions to enhance our understanding of the dynamic interplay between diabetes, the microbiome, and inflammation. We welcome submissions addressing, but not limited to, the following areas:

  • Mechanistic insights into host–microbiome–immune interactions in diabetes pathogenesis;
  • Inflammatory pathways linking dysbiosis to insulin resistance, β-cell dysfunction, and metabolic syndrome;
  • Microbiome alterations across type 1, type 2, gestational, and secondary forms of diabetes;
  • Microbial metabolites as modulators of systemic and tissue-specific inflammation;
  • Microbiome-based biomarkers of chronic inflammation, disease risk, and therapeutic response;
  • Anti-inflammatory and microbiome-targeted interventions (dietary strategies, probiotics, prebiotics, postbiotics, synbiotics, pharmacological approaches, FMT);
  • Links between inflammation, microbiome shifts, and diabetic complications (cardiovascular, renal, neurological, ocular);
  • Translational and clinical research on microbiome–inflammation–diabetes interactions in precision medicine.

We encourage original research papers, reviews, systematic analyses, perspectives, and short communications that will advance our knowledge in this interdisciplinary field.

We look forward to receiving your valuable contributions and compiling a comprehensive resource on this timely topic.

Dr. Gratiela Pircalabioru
Dr. Octavian Savu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes mellitus
  • microbiome
  • microbiota metabolites
  • metabolic disease
  • dysbiosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

27 pages, 1855 KB  
Review
Targeting Glyoxalase-1 Pathway with Natural Compounds: A Translational Strategy to Reduce Dicarbonyl Stress and Prevent Chronic Diseases
by Masood Alam Khan and Hina Younus
Life 2026, 16(5), 822; https://doi.org/10.3390/life16050822 (registering DOI) - 15 May 2026
Viewed by 208
Abstract
Methylglyoxal (MG) is a reactive dicarbonyl compound generated mainly as a byproduct of glycolysis. Excess accumulation of MG can promote protein glycation and the formation of advanced glycation end-products (AGEs), which have been associated with oxidative stress, inflammation, mitochondrial dysfunction, and cellular damage. [...] Read more.
Methylglyoxal (MG) is a reactive dicarbonyl compound generated mainly as a byproduct of glycolysis. Excess accumulation of MG can promote protein glycation and the formation of advanced glycation end-products (AGEs), which have been associated with oxidative stress, inflammation, mitochondrial dysfunction, and cellular damage. These processes are implicated in the development of several chronic conditions, including diabetes, neurodegenerative disorders, cardiovascular disease, and age-related decline. The glyoxalase system, comprising Glyoxalase I (Glo1) and Glyoxalase II (Glo2), serves as a key cellular defense mechanism that detoxifies MG and helps maintain dicarbonyl homeostasis. Among these enzymes, Glo1 catalyzes the conversion of MG into less reactive intermediates in a glutathione (GSH)-dependent manner. A range of natural compounds and dietary phytochemicals, including sulforaphane, resveratrol, α-lipoic acid, selenium, vitamin D3, and N-acetylcysteine, have been reported to modulate Glo1 activity through transcriptional regulation, antioxidant effects, or support of intracellular GSH levels. Evidence from preclinical and limited human studies suggests that these compounds may help reduce MG burden and AGE formation, although their effects are often indirect and context-dependent. However, several challenges remain, including variable bioavailability, dose-dependent responses, disease-specific differences in Glo1 regulation, and the lack of standardized biomarkers and adequate clinical validation. This review examines the MG–Glo1 axis as a mechanistic framework linking metabolic stress to disease and evaluates natural compounds as context-dependent modulators of this pathway. By integrating mechanistic insights with emerging in vivo and clinical evidence, this work highlights the potential, while acknowledging the limitations, of targeting Glo1 as a translational strategy for managing glycation-associated disorders. Full article
Show Figures

Figure 1

Back to TopTop